SLSahine Lameire

Sahine Lameire

*This is an algorithmically generated author record based on publicly available information.

Sahine Lameire has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Revisiting endothelial tropism of SARS-CoV-2 using a cell-specific hACE2 mouse model

    by Sahine Lameire, Nincy Debeuf, Julie Deckers, Caroline De Wolf, Manon Vanheerswynghels, Wendy Toussaint, Lize De Vlieger, Lien Van Hoecke, Arnout Bruggeman, Sieglinde De Cae, et al.

    Severe COVID-19 is frequently associated with vascular complications, raising ongoing debate about whether SARS-CoV-2 can directly infect endothelial cells and thereby contribute to disease pathogenesis. Although endothelial cells express angiotensin-converting enzyme 2 (ACE2), the in vivo relevance of endothelial-restricted viral tropism remains unclear. To directly assess the consequences of endothelial-restricted SARS-CoV-2 tropism in vivo , we generated a transgenic mouse model expressing human ACE2 under control of the endothelial-specific Cdh5 promoter ( Cdh5 -hACE2). Despite confirmed pulmonary endothelial expression and protein presence of hACE2, SARS-CoV-2 infection of Cdh5 -hACE2 mice did not induce clinical illness, detectable viral replication, immune cell influx in the lung, or histopathological abnormalities in the lung or brain. These findings indicate that endothelial-restricted SARS-CoV-2 tropism alone is insufficient to drive productive infection and clinical disease in vivo , suggesting that endothelial involvement in COVID-19 likely arises in the context of broader cellular infection or systemic host responses rather than from primary endothelial infection. IMPORTANCE: Although SARS-CoV-2 primarily infects the upper and lower airways, COVID-19 was quickly recognized as a multi-organ disease, in which vascular complications are a recurring feature. This has raised the possibility that direct infection of endothelial cells contributes to disease pathogenesis. However, whether vascular injury arises from productive endothelial infection or instead represents a secondary consequence of systemic inflammation remains unresolved. To directly disentangle these possibilities and define the in vivo consequences of endothelial-restricted viral tropism, we generated a transgenic mouse model expressing human ACE2 under the control of the endothelial-specific Cdh5 promoter ( Cdh5 -hACE2).

  • Open Access

    Modeling epithelial and endothelial cell tropism for SARS-CoV-2 through restricted transgenic hACE2 expression in mice

    by Sahine Lameire, Nincy Debeuf, Julie Deckers, Caroline De Wolf, Manon Vanheerswynghels, Wendy Toussaint, Lize De Vlieger, Lien Van Hoecke, Sieglinde De Cae, Bert Schepens, et al.

    Given the ongoing evolution of SARS-CoV-2 and the historical emergence of other highly transmissible coronaviruses like SARS-CoV and HCoV-NL63, in vivo coronavirus research remains crucial even when the COVID-19 pandemic is receding. Due to restricted tropism of SARS-CoV-2 and other coronaviruses for mouse cells, model systems of infection rely on transgenic expression of the entry receptor human ACE2 (hACE2). Available hACE2 transgenic models using the Krt18 promotor express the receptor across multiple cell types and organ systems, leading to multiple disease features including pneumonia, vascular compromise and neuro-inflammation, that reflect the multi-organ nature of COVID-19. To disentangle the role of cell tropism in driving the clinical manifestations of the disease, we generated two new transgenic mouse models, Sftpa1 -hACE2 and Cdh5 -hACE2 transgenic mice, with hACE2 restricted to lung epithelium or endothelial cells respectively. In Sftpa1 -hACE2 mice, with high expression of the hACE2 receptor in lung alveolar type 2 cells, SARS-CoV-2 infection led to rapidly progressing disease, characterised by a strong neutrophilic innate immune response in the lung, followed by viral neuro-invasion and early death. Krt18 -hACE2 mice additionally recruited various dendritic cell subsets and gradually developed adaptive immunity. In Cdh5 -hACE2 Tg mice with exclusive endothelial tropism of the virus, viral inoculation via the lung or systemic circulation did not lead to viral propagation or disease manifestations, despite endothelial expression of hACE2 in the lung. These results suggest that tropism for alveolar epithelial cells increases disease severity, while endothelial cell tropism per se does not drive the vascular consequences often seen in COVID-19 patients. Our new transgenic mouse models will be helpful to dissect how cell tropism contributes to the clinical manifestations of coronavirus infection.

  • Open Access

    TCR transgenic clone selection guided by immune receptor analysis and single cell RNA expression of polyclonal responders

    by Nincy Debeuf, Sahine Lameire, Manon Vanheerswynghels, Julie Deckers, Caroline De Wolf, Wendy Toussaint, Rein Verbeke, Kevin Verstaen, Hamida Hammad, Stijn Vanhee, et al.

    Since the precursor frequency of naïve T cells is extremely low, investigating the early steps of antigen-specific T cell activation is challenging. To overcome this detection problem, adoptive transfer of a cohort of T cells purified from T cell receptor (TCR) transgenic donors has been extensively used but is not readily available for emerging pathogens. Constructing TCR transgenic mice from T cell hybridomas is a labor-intensive and sometimes erratic process, since the best clones are selected based on antigen-induced CD69 upregulation or IL-2 production in vitro, and TCR chains are PCR-cloned into expression vectors. Here, we exploited the rapid advances in single cell sequencing and TCR repertoire analysis to select the best clones without hybridoma selection, and generated CORSET8 mice (CORona Spike Epitope specific CD8 T cell), carrying a TCR specific for the Spike protein of SARS-CoV-2. Implementing newly created DALI software for TCR repertoire analysis in single cell analysis enabled the rapid selection of the ideal responder CD8 T cell clone, based on antigen reactivity, proliferation and immunophenotype in vivo. Identified TCR sequences were inserted as synthetic DNA into an expression vector and transgenic CORSET8 donor mice were created. After immunization with Spike/CpG-motifs, mRNA vaccination or SARS-CoV2 infection, CORSET8 T cells strongly proliferated and showed signs of T cell activation. Thus, a combination of TCR repertoire analysis and scRNA immunophenotyping allowed rapid selection of antigen-specific TCR sequences that can be used to generate TCR transgenic mice.

  • Open Access

    TCR transgenic clone selection guided by immune receptor analysis and single cell RNA expression of polyclonal responders

    by Nincy Debeuf, Sahine Lameire, Manon Vanheerswynghels, Julie Deckers, Caroline De Wolf, Wendy Toussaint, Rein Verbeke, Kevin Verstaen, Hamida Hammad, Stijn Vanhee, et al.

    Since the precursor frequency of naïve T cells is extremely low, investigating the early steps of antigen-specific T cell activation is challenging. To overcome this detection problem, adoptive transfer of a cohort of T cells purified from T cell receptor (TCR) transgenic donors has been extensively used but is not readily available for emerging pathogens. Constructing TCR transgenic mice from T cell hybridomas is a labor-intensive and sometimes erratic process, since the best clones are selected based on antigen-induced CD69 upregulation or IL-2 production in vitro , and TCR chains are PCR-cloned into expression vectors. Here, we exploited the rapid advances in single cell sequencing and TCR repertoire analysis to select the best clones without hybridoma selection, and generated CORSET8 mice ( COR ona S pike E pitope specific CD8 T cell), carrying a TCR specific for the Spike protein of SARS-CoV-2. Implementing newly created DALI software for TCR repertoire analysis in single cell analysis enabled the rapid selection of the ideal responder CD8 T cell clone, based on antigen reactivity, proliferation and immunophenotype in vivo. Identified TCR sequences were inserted as synthetic DNA into an expression vector and transgenic CORSET8 donor mice were created. After immunization with Spike/CpG-motifs, mRNA vaccination or SARS-CoV2 infection, CORSET8 T cells strongly proliferated and showed signs of T cell activation. Thus, a combination of TCR repertoire analysis and scRNA immunophenotyping allowed rapid selection of antigen-specific TCR sequences that can be used to generate TCR transgenic mice.

  • A complement atlas identifies interleukin-6–dependent alternative pathway dysregulation as a key druggable feature of COVID-19

    by Karel F. A. Van Damme, Levi Hoste, Jozefien Declercq, Elisabeth De Leeuw, Bastiaan Maes, Liesbet Martens, Roos Colman, Robin Browaeys, Cédric Bosteels, Stijn Verwaerde, et al.

    Improvements in COVID-19 treatments, especially for the critically ill, require deeper understanding of the mechanisms driving disease pathology. The complement system is not only a crucial component of innate host defense but can also contribute to tissue injury. Although all complement pathways have been implicated in COVID-19 pathogenesis, the upstream drivers and downstream effects on tissue injury remain poorly defined. We demonstrate that complement activation is primarily mediated by the alternative pathway, and we provide a comprehensive atlas of the complement alterations around the time of respiratory deterioration. Proteomic and single-cell sequencing mapping across cell types and tissues reveals a division of labor between lung epithelial, stromal, and myeloid cells in complement production, in addition to liver-derived factors. We identify IL-6 and STAT1/3 signaling as an upstream driver of complement responses, linking complement dysregulation to approved COVID-19 therapies. Furthermore, an exploratory proteomic study indicates that inhibition of complement C5 decreases epithelial damage and markers of disease severity. Collectively, these results support complement dysregulation as a key druggable feature of COVID-19.


  • Open Access

    Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike

    by Sieglinde De Cae, Inge Van Molle, Loes van Schie, Sophie R. Shoemaker, Julie Deckers, Nincy Debeuf, Sahine Lameire, Wim Nerinckx, Kenny Roose, Daria Fijalkowska, et al.

    Currently circulating SARS-CoV-2 variants have gained complete or significant resistance to all SARS-CoV-2-neutralizing antibodies that have been used in the clinic. Such antibodies can prevent severe disease in SARS-CoV-2 exposed patients for whom vaccines may not provide optimal protection. Here, we describe single-domain antibodies (VHHs), also known as nanobodies, that can broadly neutralize SARS-CoV-2 with unusually high potency. Structural analysis revealed their binding to a unique, highly conserved, membrane proximal, quaternary epitope in the S2 subunit of the spike. Furthermore, a VHH-human IgG1 Fc fusion, efficiently expressed in Chinese hamster ovary cells as a stable antibody construct, protected hamsters against SARS-CoV-2 replication in a therapeutic setting when administered systemically at low dose. This VHH-based antibody represents a new candidate anti-COVID-19 biologic that targets the Achilles heel of the viral spike.


  • The Ste20 kinase TAOK3 controls the development, homeostasis and activation of αβ T cells

    by S Lameire, L Vandersarren, H Hammad, B Lambrecht

    T-cell antigen receptor (TCR) signalling is essential for the activation, proliferation, and effector function of T cells. While key steps in the activation of T cells are well-established, the precise molecular circuits downstream of TCR remain a subject of intense investigation. We set out to better characterize the role of a poorly understood MAP3 kinase, Thousand and one kinase 3 (TAOK3), in T cell homeostasis and antiviral responses. Therefore, our lab generated a Taok3 deficient mouse model by means of CRISPR/Cas. Whereas early thymic development was favoured, Taok3-/- thymocytes were compromised beyond the double positive (DP) stage. However, a considerable amount of naïve T cells still made it to the periphery, and these cells expressed higher levels of CD5 and CD44, indicative of a higher degree of self-reactivity of the TCR repertoire, most likely needed to overcome any defects caused by the lack of TAOK3. Naïve cells were yet lost in the periphery due to defective homeostatic signalling and were unable to differentiate well into effector cells upon seeing foreign antigens. As measured using techniques such as alloMLR, and OVA-specific responses in vitro as well as antiviral responses against Pneumonia Virus of Mice (PVM) and SARS-CoV-2 in vivo. Employing a Nur77-eGFP reporter system, we were able to show that activated Taok3-/- T cells did probably not reach the threshold of accumulated TCR signalling to undergo proliferation. With these preliminary results, we show that TAOK3 is specifically required for proper canonical TCR signalling, both during developmental stages in the thymus as well as during homeostatic survival and effector signalling in the periphery.